Contraception
Volume 81, Issue 6 , Pages 501-509 , June 2010

Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen

  • Cosima Brucker

      Affiliations

    • Klinikum Nürnberg Nord, Klinik für Frauenheilkunde, Prof.-Ernst-Nathan-Str. 1, 90419 Nürnberg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 911 3982222.
    • ,
  • Bernard Hedon

      Affiliations

    • Hôpital Arnaud de Villeneuve, 371, Av. Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    • ,
  • Hok Sien The

      Affiliations

    • St. Antonius Ziekenhuis, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands
    • ,
  • Kornelia Höschen

      Affiliations

    • Grünenthal GmbH, 52099 Aachen, Germany
    • ,
  • Natascha Binder

      Affiliations

    • Grünenthal GmbH, 52099 Aachen, Germany
    • ,
  • Annette Christoph

      Affiliations

    • Grünenthal GmbH, 52099 Aachen, Germany

Received 16 September 2008 ,Revised 11 January 2010 ,Accepted 13 January 2010.

References 

  1. Combined oral contraceptives . A statement by the committee on safety of drugs. Br Med J. 1970;2:231–232
  2. Jeffcoate TN. R.C.O.G. statement on oral contraceptives. Br Med J. 1970;2:293
  3. Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B. [Recommendations for oral contraception. 20th Professional Meeting of the Zurich Discussion Group, April 1998]. Gynakol Geburtshilfliche Rundsch. 1998;38:164–165
  4. Birkhauser M, Braendle W, Breckwoldt M, Keller PJ, Kuhl H, Runnebaum B. [Recommendations for oral contraception. 24th meeting of the “Zurich Discussion Circle”]. Gynakol Geburtshilfliche Rundsch. 2000;40:172–175
  5. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
  6. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest. 2002;22:221–231
  7. Plewig G, Cunliffe W, Binder N, Höschen K. Efficacy of an oral contraceptive containing ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg (EE/CMA; Belara®) in moderate acne resolution: a randomised, double-blind, placebo-controlled phase III trial. Contraception. 2009;80(1):25–33
  8. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception. 2003;67:305–312
  9. Winkler U, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care. 1999;4:145–154
  10. Worret I, Arp W, Zahradnik H, Andreas J, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 2001;203:38–44
  11. Zahradnik H, Goldberg J, Andreas J. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception. 1998;57:103–109
  12. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) — an open-label, prospective, noncontrolled, office-based Phase III study. Contraception. 2008;77:337–343
  13. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007;76:84–90
  14. Gallo M, Nanda K, Grimes D, Schulz K. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005;CD003989
  15. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115–120
  16. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect. 1996;28:154–158
  17. In: Pre-authorisation Evaluation of Medicines for Human Use. Guideline on clinical investigation of steroid contraceptives in women. London: EMEA; 2006;p. 1–6Available at: http://www.ema.europa.eu/pdfs/human/ewp/051998en.pdf
  18. Potter RG. Application of the life table techniques to measurements of contraceptive effectiveness. Demography. 1966;3:297–304
  19. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986;34:253–260
  20. Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964–88. Am J Public Health. 1991;81:90–96
  21. Wallach M, Grimes DA. Modern oral contraception. 1st ed. Totowa, NJ: Emron; 2000;
  22. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–266
  23. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
  24. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70:191–198
  25. Archer DF, Maheux R, DelConte A, O'Brien FB. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol. 1999;181:39–44
  26. Cibula D, Karck U, Weidenhammer HG, Kunz J, Alincic S, Marr J. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg. Clin Drug Investig. 2006;26:143–150
  27. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Dusterberg B. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene. Contraception. 2001;64:99–105
  28. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception. 1995;51:283–288
  29. Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74:220–223
  30. Belsey EM, Carlson N. The description of menstrual bleeding patterns: towards fewer measures. Stat Med. 1991;10:267–284
  31. Gestodene, Study, Group, 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg. Eur J Contracept Reprod Health Care. 1999;4(Suppl. 2):9–15
  32. Gruber DM, Huber JC, Melis GB, Stagg C, Parke S, Marr J. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug. Treat Endocrinol. 2006;5:115–121
  33. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. Eur J Contracept Reprod Health Care. 1998;3:179–189
  34. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception. 2004;69:469–476
  35. Dando TM, Curran MP. Low-dose ethinylestradiol/levonorgestrel. Drugs. 2005;65:2299–2306discussion 307-8
  36. Godsland IF, Winkler U, Lidegaard O, Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs. 2000;60:721–869
  37. Tchaikovski S, Tans G, Rosing J. Venous thrombosis and oral contraceptives: current status. Women's Health. 2006;2:761–772
  38. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527–1535
  39. Crook D. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group. Contraception. 1997;55:219–224
  40. Endrikat J, Klipping C, Cronin M, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002;65:215–221
  41. Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004;69:271–278
  42. Wysocki . A survey of American women regarding the use of oral contraceptives and weight gain [abstract]. Int J Gynecol Obstet. 2000;70:114
  43. van de Weijer P. What women want and what their doctors need — how do women evaluate the quality of contraceptive methods and products introduced by their gynaecologist? A different perspective. Eur J Contracept Reprod Health Care. 2005;10(Suppl 1):2–6
  44. Sanders S, Graham C, Bass J, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–58
  45. Mall-Haefeli M. Die Wirkung der Androgene auf das Zyklusgeschehen. In:  Loch EG,  Schramm G editor. Chlormadinonacetat bei Androgenisierungserscheinungen. Schattauer: Stuttgart; 1995;p. 42–55
  46. Lucky A, Biro F, Huster G, Leach A, Morrison J, Ratterman J. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol. 1994;130:308–314
  47. Kligman A. Postadolescent acne in women. Cutis. 1991;48:75–77
  48. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2007;CD004425
  49. Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76:342–347
  50. Kuhl H. In:  Loch EGSG editors. Chemie und Pharmakologie von Chlormadinonacetat Chlormadinonacetat bei Androgenisierungserscheinungen. Schattauer: Stuttgart; 1995;
  51. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63:463–492

☆ Conflict of interest statement: Professor Brucker is a member of an advisory board on 0.02 mg EE/2 mg CMA sponsored by Grünenthal GmbH, Aachen, Germany.

PII: S0010-7824(10)00012-0

doi: 10.1016/j.contraception.2010.01.011

Contraception
Volume 81, Issue 6 , Pages 501-509 , June 2010

Article Tools

* Image Usage & Resolution